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Recent work has identified dysfunctional Hippo signaling to be involved in maintenance and progression of various
human cancers, although data on clear cell renal cell carcinoma (ccRCC) have been limited. Here, we provide
evidence implicating aberrant Hippo signaling in ccRCC proliferation, invasiveness, and metastatic potential.
Nuclear overexpression of the Hippo target Yes-associated protein (YAP) was found in a subset of patients with
ccRCC. Immunostaining was particularly prominent at the tumor margins and highlighted neoplastic cells invading
the tumor-adjacent stroma. Short hairpin RNA-mediated knockdown of YAP significantly inhibited proliferation,
migration, and anchorage-independent growth of ccRCC cells in soft agar and led to significantly reduced murine
xenograft growth. Microarray analysis of YAP knockdown versus mock-transduced ccRCC cells revealed down-
regulation of endothelin 1, endothelin 2, cysteine-rich, angiogenic inducer, 61 (CYR61), and c-Myc in ccRCC cells
as well as up-regulation of the cell adhesion molecule cadherin 6. Signaling pathway impact analysis revealed
activation of the p53 signaling and cell cycle pathways as well as inhibition of mitogen-activated protein kinase
signaling on YAP down-regulation. Our data suggest CYR61 and c-Myc as well as signaling through the endothelin
axis as bona fide downstream effectors of YAP and establish aberrant Hippo signaling as a potential therapeutic
target in ccRCC.
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Renal cell carcinoma (RCC) accounts for about 2% to 3% of all
malignant diseases in adults with clear cell RCC (ccRCC) being the most
common histologic subtype that represents 70% to 80% of all cases [1].
Despite the emergence of novel targeted therapies such as antiangioge-
netic drugs and mammalian target of rapamycin inhibitors over the last
decade, the prognosis of metastatic renal cancer remains poor with 5-year
survival rates of less than 10% [2]. This grim prognosis poses the need for
a better understanding of the underlying molecular mechanisms driving
metastatic ccRCC to be able to develop novel therapeutic approaches.
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conserved and to function as a critical regulator of organ size control.
Moreover, we and others have recently been able to show that Hippo
signaling exerts a dramatic oncogenic potential in several human
malignancies [3,4]. Although germ-line and somatic mutations of the
Hippo pathway core components are rare, deregulation and
subsequent overexpression of Yes-associated protein (YAP) have
been observed in many human cancers [5-7]. However, as of to date,
little data exist on the role of Hippo signaling in ccRCC.
In this study, we demonstrate that Hippo signaling is activated in
ccRCC and is involved in regulating proliferation, invasiveness, and
metastatic potential. Downstream effectors of Hippo signaling in
ccRCC are characterized to identify potential targets for therapeutic
intervention.Materials and Methods
Tumor Samples and Immunohistochemistry
All tumor samples were collected from the archives of the Institute
of Pathology, University of Cologne (Cologne, Germany). The
samples were formalin fixed and paraffin embedded (FFPE) as part of
routine diagnostic procedures. Clinicopathologic data were obtained
from case records provided by the Institute of Pathology, University of
Cologne. All tumors were clinically and pathologically identified as
being the primary and only neoplastic lesion and classified according
to World Health Organization guidelines. Briefly, 3-μm-thick
sections of FFPE tumors were deparaffinized, and antigen retrieval
was performed by boiling the section in citrate buffer at pH 6 for 20
minutes. Primary antibodies used were given as follows: YAP (1:100,
#4912; Cell Signaling Technology, Danvers, MA), endothelin-2
(EDN2; 1:100, NBP1-87942; Novus Biologicals, Littleton, CO),
SAV1 (1:100, clone 3B3; Abnova, Taipei, Taiwan), and cytokeratin
(1:200, clone AE1/AE3; Dako, Glostrup, Denmark). Staining was
performed following established routine procedures, and staining
intensity was evaluated individually in a blinded fashion. Statistical
analysis was performed using Fisher exact test on GraphPad's
QuickCalcs platform (http://graphpad.com/quickcalcs/
contingency1.cfm). P b .05 was considered statistically significant.
Cell Lines
Human RCC cell lines A498 (ATCC HTB-44), Caki-2 (ATCC
HTB-47), MZ1774, B1, B3, and RCC177 were cultured in RPMI
1640 (PAA Laboratories, Pasching, Austria), supplemented with
10% FBS, 1× penicillin/streptomycin (both PAA Laboratories), as
well as 5 μg/ml plasmocin (InvivoGen, San Diego, CA). MZ1774,
B1, B3, and RCC177 are primary RCC cell lines and have been
described in [8-10]. The human RCC cell line ACHN (ATCC
CRL-1611) was maintained in Dulbecco's modified Eagle's
medium (PAA Laboratories) supplemented with 10% FBS, 1×
penicillin/ streptomycin (both PAA Laboratories), and 5 μg/ml
plasmocin (InvivoGen).
293FT cells were maintained in Dulbecco's modified Eagle's
medium containing 10% FBS, 0.1 mM non-essential amino acids, 1
mM sodium pyruvate, and 1× penicillin/ streptomycin (all PAA
Laboratories) as well as 5 μg/ml plasmocin (InvivoGen).
All cell lines were cultured in a humidified atmosphere at 37°C in
the presence of 5% CO2 and were regularly monitored for Myco-
plasma infection using a polymerase chain reaction (PCR)–based
assay as previously described [11].Lentivirus Production and Generation of Stable Cell Lines
A target set containing shRNA sequences directed against human
YAP1 in pLKO.1 lentiviral plasmids was obtained from Thermo
Scientific (Waltham, MA), and two clones, which had shown best
knockdown efficiency in preliminary experiments, were selected for
lentiviral transduction of ccRCC cell lines, designated YAPshRNA#4
(Clone No. TRCN0000107268) and YAPshRNA#5 (Clone No.
TRCN0000107269).
293FT-packaging cells were cotransfected with pCMV-VSVg,
pCMV-dR8.74, and the respective pLKO.1 plasmids using Fugene6
(Roche Applied Science, Mannheim, Germany). An empty pLKO.1
vector containing no shRNA sequence was used as a negative
“mock” control. Supernatant containing lentivirus was harvested
after 48 and 72 hours and used to transduce human ccRCC cell
lines. Puromycin selection of resistant ccRCC cells was performed,
and cells were cultured in the presence of puromycin throughout all
experiments.
Cell Viability Assays
Determination of cell viability was performed using the 3-(4,5-
dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay as previously described [12]. Briefly, 2000
cells per well were incubated in full growth media for 0, 48, or 96
hours, respectively. All experiments were set up in quadruplicates, and
results were normalized to the mean cell viability at 0 hour. CellTiter
96 Aqueous One solution (20 μl; Promega, Madison, WI) was added
to each well and absorbance at 492 nm was determined using a 96-
well plate reader (BMG Labtech, Offenburg, Germany) on
incubation of plates at 37°C for 2 hours.
Replating Efficiency Assays
Cells were seeded into six-well plates at 1000 cells per well in full
growth media. Once colonies became visible, cells were fixed with
70% ethanol and stained with a 0.05% aqueous solution of crystal
violet (Sigma-Aldrich, Steinheim, Germany). Colonies were counted
and colony counts were normalized to the mean colony count of
mock-transduced cell lines.
Soft Agar Assays
Soft agar assays were set up in six-well plates with a bottom layer
of 1% agarose (Life Technologies, Darmstadt, Germany), an
intermediate layer containing 0.6% agarose and 10,000 cells per
well, as well as a final layer of media only. Plates were incubated
for 4 weeks at 37°C and medium was exchanged once weekly.
Colonies were stained with a 0.05% aqueous solution of crystal
violet (Sigma-Aldrich) and visualized by trans-UV illumination
(Bio-Rad, Hercules, CA). Colonies were counted and colony
counts were normalized to the mean colony count of mock-
transduced cell lines.
Migration Assays
Modified Boyden chamber assays were set up in 24-well transwell
plates with 8-μm pore size filters (BD Biosciences, San Jose, CA).
Fifty thousand cells per well were applied and transwell migration
was assessed after 48 and 72 hours of incubation at 37°C,
respectively. Cells adherent at the bottom of the filter were fixed in
70% ethanol and stained with hematoxylin. Cells were counted in
three randomly selected microscopic fields and means and SDs were
calculated.
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Cells were lysed in radioimmunoprecipitation assay buffer (1%
Igepal CA 630, 0.5%Na-deoxycholate, 0.1% sodium dodecyl sulfate,
2 mM EDTA) supplemented with protease and phosphatase
inhibitor cocktails (Sigma-Aldrich). Fifty micrograms of total protein
was separated on sodium dodecyl sulfate–polyacrylamide gels and
transferred onto nitrocellulose membranes (Merck Millipore, Biller-
ica, MA). The blots were probed with antibodies against YAP,
phospho-YAP (pYAP), and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) (Cell Signaling Technology) as well as TEAD1 (Santa
Cruz Biotechnology, Dallas, TX). Secondary, HRP-coupled anti-
bodies directed against rabbit or mouse IgG, respectively, were
purchased from Cell Signaling Technology. Detection was performed
as previously described [13].Transcriptomic Profiling of MZ1774 YAP Knockdown Cells
A total of 100 ng of total RNA, isolated using the RNeasy Kit
(Qiagen, Hilden, Germany) following the standard procedure as
recommended by the manufacturer, was subjected to a single round
of in vitro transcription and biotin labeling (Illumina TotalPrep
RNA Amplification Kit; Ambion, Austin, TX). The resulting
complementary RNA was hybridized on HumanHT-12 v4.0
Expression BeadArrays (Illumina, San Diego, CA) according to
the manufacturer's protocols using an automated liquid handling
pipeline and scanned on an iScan System.
Expression data were exported as unnormalized sample and control
probe profiles from the Illumina GenomeStudio software and analyzed
using R/Bioconductor and limma. Data were quality weighed,
background-corrected, quantile-normalized, log-transformed, and ex-
plored for differentially expressed genes with a false discovery rate
(FDR) of 0.05 using Bayesian statistics. Differential regulation of
signaling pathways was performed using the signaling pathway impact
analysis algorithm as previously described elsewhere [14].RNA Extraction and Reverse Transcription–Quantitative PCR
For real-time reverse transcription–quantitative PCR (RT-qPCR)
analysis, cells were lysed and total RNA was extracted using RNeasy
Mini Kit including an on-column DNase digestion step (both
Qiagen). RNA was reverse transcribed using random primers and
the High Capacity cDNA Reverse Transcription Kit (Life
Technologies) according to the manufacturer's specifications. Real-
time qPCR for human YAP, endothelin-1 (EDN1), EDN2, V-myc
myelocytomatosis viral oncogene homolog (avian) (MYC), cadherin-
6 (CDH6), cysteine-rich, angiogenic inducer, 61 (CYR61),
thrombospondin-1 (THBS1), and growth arrest and DNA
damage-inducible, beta was performed using the SYBR Premix Ex
Taq (Tli RNase H Plus) Kit (Takara Bio Europe, Saint-Germain-
en-Laye, France) on a Reaplex2 Mastercycler Real-Time PCR
System (Eppendorf, Hamburg, Germany). Relative fold expression
levels were determined using the 2(−ΔΔCt) method [15], withGAPDH
used as a housekeeping control.
Chromatin Immunoprecipitation
TEAD1-binding sites found in 5 kb upstream of the transcription
start site of the indicated genes were considered and primer pairs for
qPCR measurement of immunoprecipitated promoter fragments
flanking the putative binding regions were designed. Chromatin from
formaldehyde cross-linked MZ1774 cells was isolated and sheared toan average fragment size of 600 bp using a probe sonicator (Branson
Ultrasonics, Danbury CT). Aliquots of pre-cleared, diluted chroma-
tin was immunoprecipitated using antibodies against YAP or TEAD1
(both Santa Cruz Biotechnology), and immunoprecipitated frag-
ments were pulled down using protein A agarose beads. Immuno-
precipitations using normal mouse IgG (Santa Cruz Biotechnology)
as well as anti-acetyl histone H3 (Merck Millipore) were carried out
simultaneously as negative and positive controls. Immunoprecipitated
DNA fragments were purified using the phenol/chloroform method
and RT-qPCR for the putative binding regions was performed on all
chromatin immunoprecipitation (ChIP) preparations. Fold enrich-
ments were calculated in relation to the negative controls using
normal mouse IgG.
Xenograft Experiments
All animal experiments described were approved by the Govern-
ment of the State of North Rhine-Westphalia (Permit No. 8.87-
50.10.37.09.264). Mice were maintained according to the guidelines
of the Federation of European Laboratory Animal Science
Associations.
To generate subcutaneous xenografts, ACHNYAP knockdown and
ACHN mock-transfected cells in log growth phase were harvested by
trypsinization, counted, and subsequently injected into the flanks of
five male athymic CD1nu/nu mice (Charles River, Wilmington, MA)
as previously described [16]. In brief, 2.5 × 106 cells suspended in a
total volume of 250 μl [full growth medium/Matrigel (BD Bio-
sciences), 1:1 (vol/vol), prechilled to 4°C] were subcutaneously
injected into the flanks of 6- to 8-week-old mice. Starting 10 days after
the injection of tumor cells, tumor dimensions were determined twice
a week by use of digital calipers (Milomex, Pulloxhill, United
Kingdom), and tumor volumes (V) were determined as V = 1/2(ab2),
with a being the longest and b the shortest orthogonal tumor
diameter. Mice were sacrificed after 6 weeks, and tumors were
harvested and cryopreserved or formalin-fixed for later analysis.
Statistical Analysis
Fisher exact test and two-tailed Student's t-tests were done using
GraphPad Prism for Macintosh, version 4.0a. P b .05 was regarded to
be statistically significant. Unless indicated otherwise, results are
shown as means ± SEM.
Results
The Hippo Pathway Effector Yes-Associated Protein Is
Overexpressed in ccRCC
In a panel of seven ccRCC cell lines, basal YAP expression was
found in all cell lines examined, although expression levels varied
greatly, with some cell lines expressing very high levels of YAP, while
expression was minimal in others. The phosphorylated form of the
transcriptional coactivator constitutes the inactive form of YAP. We
found that cell lines with high basal levels of total YAP contained
minimal (ACHN) to absent (MZ1774) levels of pYAP pointing
toward high transcriptional activity of YAP. We further found
consistently high levels of TEAD1, a major interaction partner of
YAP, in all cell lines analyzed (Figure 1).
Next, expression of the Hippo pathway component SAV1 and of
the nuclear effector of the Hippo pathway YAP was assessed in 31
ccRCC cases by immunohistochemistry. In non-neoplastic renal
parenchyma, we observed strong nuclear YAP expression in podocytes
and differential expression in the proximal and distal compartments of
Table 1. Loss of SAV1 Immunoreactivity Correlates with Nuclear Localization of YAP.
YAP Expression
Cytoplasmic Nuclear Total
SAV1 Positive 13 2 15
Weak or negative 6 10 16
Total 19 12 31
Fisher exact test, P = .0091.
Figure 1. Expression of YAP in ccRCC cell lines. Basal expression
of YAP was observed in all ccRCC cell lines examined, whereas
expression of the inactive form pYAP was minimal to absent in cell
lines expressing high basal levels of YAP. The transcription factor
TEAD1, a major interaction partner of YAP, was found in all ccRCC
cell lines analyzed.
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consistently exhibited strong cytoplasmic and nuclear immunolabel-
ing, significantly weaker YAP expression was observed in the proximal
tubules, the putative site of origin of ccRCC (Figure 2, A and B). In
RCC tissue samples, we found nuclear up-regulation of YAP
expression compared to the proximal tubules in the adjacent normal
tissue in 20 of 31 cases (65%; P b .0001).
Of note, YAP staining intensity was considerably more prominent
at the tumor margins representing the invasive front, and in severalFigure 2. Loss of SAV1 expression results in nuclear sequestration of
associated with a highly invasive phenotype. Immunohistochemistry o
of normal renal parenchymawith proximal tubule cells exhibiting only
moderate to strong YAP immunoreactivity (B). YAP positivity was str
tumor-adjacent stroma (D, F) that also exhibit positivity for cytokerati
with sequestration of YAP expression to the nucleus of tumor cells (J,
YAP expression (H, I).patients that showed high expression levels of YAP, we observed single
keratin-positive tumor cells invading the surrounding lymphocyte
rich stroma, suggesting a possible role of Hippo signaling in ccRCC
tumor cell invasion in vivo (Figure 2, C–G).
We cannot report correlation of YAP positivity with tumor grade
based on this small sample size, with 22 of 31 cases being
histopathologically classified as grade 2. However, vascular invasion
or lymph node metastases were reported for 9 of 30 cases, and of
these, 7 exhibited marked YAP positivity.Loss of SAV1 Immunoreactivity Correlates with Nuclear
Localization of YAP
Immunohistochemistry revealed strong cytoplasmic SAV1 expres-
sion in normal tubular epithelial cells, but curiously immunolabeling
was lost in adjacent neoplastic cells in 16 of 31 cases. Moreover,
weak or absent SAV1 expression was found to correlate with nuclear
localization of YAP, whereas sustained SAV1 expression vice versa
caused nuclear exclusion of YAP (P = .0091; see Table 1 and
Figure 2, H–K).YAP in patients with ccRCC, and coexpression of YAP and keratin is
f tumor tissues of 31 patients with ccRCC showed distinct staining
minimal to weak nuclear staining (A), whereasmost tumors showed
onger at the tumor margins (C) and highlights single cells invading
n (E, G). Loss of SAV1 immunoreactivity was frequently associated
K), whereas retained SAV1 expression results in mainly cytoplasmic
Figure 3. YAP down-regulation impairs proliferation and migration of ccRCC cell lines. shRNA-mediated knockdown of YAP in three
different ccRCC cell lines that express high levels of YAP (A) resulted in significantly reduced cell viability as determined byMTS assay (B).
YAP down-regulation further resulted in marked inhibition of ccRCC migration in modified Boyden chamber assays. Transwell migration
through 8-μmpore filters was assessed after 48 and 72 hours. A pronounced decrease in cell numbers was found for the YAP knockdown
mass clones. *P b .05, **P b .01, ***P b .001 (C). Three randomly selected microscopic fields of representative experiments were
selected and cells were counted. Results are shown as means ± SD.
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and Blocks Migration of ccRCC Cells In Vitro
To further study the role of Hippo signaling in renal cell cancer and
to evaluate its potential as a putative therapeutic target, three ccRCC cell
lines with high basal YAP expression levels—A498, ACHN, and
MZ1774—were picked and dysfunctional Hippo signaling and
aberrant YAP activity were abrogated by shRNA-mediated knockdown.
For each of the respective parental cell lines, at least two different
shRNA sequences directed against YAP (designated as “YAPshRNA#4”
and “YAPshRNA#5”) were used and compared to untransduced as well
as to mock-transduced mass clones to minimize the risk of unspecific,
off-target effects. Consistent stable knockdown of endogenous YAP was
confirmed by Western blot analysis (Figure 3A).
In all of the three cell lines examined, YAP knockdown led to a
significant time-dependent reduction of net cell growth compared to
mock-transduced cells as determined using MTS assays (Figure 3B).
Next, effects of YAP knockdown on in vitro cell migration was
assessed by employing modified Boyden chamber assays. Of note, a
marked reduction of ccRCC migration was observed in response to
YAP knockdown in all three cell lines examined (P b .001;
Figure 3C), in line with the observation of YAP being associated to
an invasive phenotype in vivo, as already discussed above. All
experiments were done in triplicates and repeated at least once.
YAP Knockdown Diminishes Colony Formation and
Anchorage-Independent Growth of ccRCC Cells
The ability to form colonies from single cells and the ability to
grow anchorage independently are considered two important
hallmarks of cancer cells in vitro. To determine potential effects ofYAP knockdown on the former of these cellular functions in ccRCC,
replating efficiency assays were performed using single cell suspen-
sions. Of note, the ability of ACHN-YAP-shRNA#4 cells to form
colonies from single cells in this setting was significantly reduced
compared to mock-transduced ACHN controls (mean reduction of
colony counts by 66.3 ± 0.05%, n = 6, P b .0001; Figure 4A). Of
interest, the colonies formed by YAP knockdown cells were not only
less numerous but also smaller in size, reflecting reduced in vitro net
cell growth as already observed previously in MTS assays.
Anchorage-independent growth and colony formation in soft agar
is a widely accepted in vitro surrogate phenotype for malignant
transformation. YAP knockdown potently and reproducibly abro-
gated anchorage-independent growth of ACHN cells in soft agar
(reduction of colony counts by more than 90 ± 0.02%, n = 6,
P b .0001; Figure 4B). Similar to what was seen in replating assays,
the remaining colonies formed by ACHN-YAP-shRNA mass clones
were not only sparse in number but also significantly smaller
compared to their mock-transduced counterparts in this three-
dimensional culture setting.
YAP Knockdown Inhibits Tumor Growth in a Subcutaneous
Xenograft Model of ccRCC
On the basis of these encouraging in vitro data suggesting a
dependency of ccRCC cells on signaling through the Hippo pathway
for maintenance of a malignant phenotype, we next tried to assess the
in vivo relevance of this finding using a subcutaneous xenograft
model. Male athymic CD1nu/nu nude mice, 6 to 8 weeks of age, were
injected subcutaneously with 2.5 × 106 ACHN-YAP-shRNA or
ACHN mock cells into both flanks. Tumor volumes were assessed
Figure 4. shRNA-mediated YAP knockdown reduces colony formation and abates anchorage-independent growth of ccRCC cells. Down-
regulation of YAP significantly reduced the number of colonies formed in replating efficiency assays (A) as well as anchorage-independent
growth in soft agar of the ccRCC cell line ACHN (B). Representative images and combined colony counts of three independent
experiments are shown.
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xenograft growth of ACHN-YAP-shRNA cells was significantly
delayed compared to ACHN mock controls (P = .0182; Figure 6, A,
left panel, and B), while at the same time the overall body mass of
xenograft-bearing mice was not significantly altered between the two
study arms (Figure 6A, right panel).
At 5 weeks after injection, mice were sacrificed, and tumors were
harvested for histopathologic and immunohistochemical evaluationTable 2. Upregulated Genes in MZ1774 YAP Knockdown Cells.
Gene ID Symbol Gene Name
84952 CGNL1 Cingulin-like 1
5265 SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
80117 ARL14 ADP-ribosylation factor-like 14
10344 CCL26 Chemokine (C-C motif) ligand 26
1004 CDH6 Cadherin-6, type 2, K-cadherin (fetal kidney)
266977 GPR110 G protein–coupled receptor 110
283460 HNF1A-AS1 HNF1A antisense RNA 1 (non-protein coding)
55195 C14orf105 Chromosome 14 open reading frame 105
266977 GPR110 G protein–coupled receptor 110
11074 TRIM31 Tripartite motif containing 31
55775 TDP1 Tyrosyl DNA phosphodiesterase 1
283209 PGM2L1 Phosphoglucomutase 2-like 1
5265 SERPINA1 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
11221 DUSP10 Dual specificity phosphatase 10
3767 KCNJ11 Potassium inwardly rectifying channel, subfamily J, member
2353 FOS FBJ murine osteosarcoma viral oncogene homolog B
56829 ZC3HAV1 Zinc finger CCCH-type, antiviral 1
158295 MGC24103 Hypothetical MGC24103
7327 UBE2G2 Ubiquitin-conjugating enzyme E2G2
56664 VTRNA1-1 Vault RNA 1-1or snap-frozen for mRNA extraction and subsequent real-time RT-
qPCR analysis, respectively.
Microarray Analysis of MZ1774 YAP Knockdown Cells
Identifies Putative Downstream Targets of YAP in ccRCC
cDNA microarray analysis of MZ1774 YAPshRNA mass clones
revealed 14 genes that were upregulated more than two-fold (Table 2)
and another 42 genes that were downregulated by more than 50%Accession No. Fold Change P Value
NM_001252335.1 2.97 2.23E−11
antitrypsin), member 1 NM_000295.4 2.49 6.10E−07
NM_025047.2 2.49 1.91E−07
NM_006072.4 2.47 2.00E−05
NM_004932.3 2.27 7.61E−10
NM_153840.2 2.22 5.90E−07
NR_024345.1 2.11 2.20E−04
NM_018168.2 2.07 4.97E−03
NM_153840.2 2.06 1.09E−06
NM_007028.3 2.04 1.00E−05
NM_001008744.1 2.03 7.20E−04
NM_173582.3 2.02 5.00E−05
antitrypsin), member 1 NM_000295.4 2.02 1.30E−04
NM_007207.4 2.01 1.00E−04
16 NM_000525.3 1.97 1.00E−05
NM_005252.3 1.97 5.91E−02
NM_020119.3 1.97 1.50E−04
XR_108934.3 1.96 4.91E−03
NM_003343.5 1.95 8.77E−03
NR_026703.1 1.94 1.20E−04
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eight targets were picked for validation by real-time qPCR. All of
those eight targets found to be downregulated by microarray analysis
were confirmed to be downregulated using RT-qPCR, and CDH6 as
an example of a target found to be overexpressed in the microarray
analysis was also found to be upregulated using RT-qPCR
(Figure 5A).
Increasing recent evidence suggests that the complexity of cancer
genomic and transcriptomic patterns might only be fully appreciated
in its entirety when moving away from analyzing abnormalities on a
single-gene basis and toward a pathway-based approach. This
fundamental paradigm shift is currently being more and more
commonly adapted and is finding its way into basic understanding of
cancer research as well as into everyday routine clinical applications in
the field of medical oncology [17,18]. To identify signaling pathways
potentially affected by altered signaling through the Hippo/warts axis,
signaling pathway impact analysis was performed as previously
described elsewhere [14]. Of note, the top three pathways found to be
affected were the p53, MAP kinase, as well as cell cycle progression
pathways, all of which have long been well established as centrallyTable 3. Downregulated Genes in MZ1774 YAP Knockdown Cells.
Gene ID Symbol Gene Name
1907 EDN2 Endothelin-2
1906 EDN1 Endothelin-1
7057 THBS1 Thrombospondin-1
4616 GADD45B Growth arrest and DNA-damage-inducible, beta
3491 CYR61 Cysteine-rich, angiogenic inducer, 61
10175 CNIH Cornichon homolog (Drosophila)
1646 AKR1C2 Aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase
bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type
4609 MYC V-myc myelocytomatosis viral oncogene homolog (avian)
523 ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A
4609 MYC V-myc myelocytomatosis viral oncogene homolog (avian)
6520 SLC3A2 Solute carrier family 3 (activators of dibasic and neutral amino acid
284018 C17orf58 Chromosome 17 open reading frame 58
10413 YAP1 Yes-associated protein 1
81788 NUAK2 NUAK family, SNF1-like kinase, 2
1316 KLF6 Kruppel-like factor 6
586 BCAT1 Branched chain amino acid transaminase 1, cytosolic
81788 NUAK2 NUAK family, SNF1-like kinase, 2
6526 SLC5A3 Solute carrier family 5 (sodium/myo-inositol cotransporter), member 3
59345 GNB4 Guanine nucleotide binding protein (G protein), beta polypeptide 4
54206 ERRFI1 ERBB receptor feedback inhibitor 1
27032 ATP2C1 ATPase, Ca++ transporting, type 2C, member 1
84706 GPT2 Glutamic pyruvate transaminase (alanine aminotransferase) 2
9518 GDF15 Growth differentiation factor 15
406991 MIR21 MicroRNA 21
59272 ACE2 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2
8140 SLC7A5 Solute carrier family 7 (amino acid transporter light chain, L system)
51125 GOLGA7 Golgin A7
4703 NEB Nebulin
79660 PPP1R3B Protein phosphatase 1, regulatory (inhibitor) subunit 3B
10175 CNIH Cornichon homolog (Drosophila)
57761 TRIB3 Tribbles homolog 3 (Drosophila)
388272 C16orf87 Chromosome 16 open reading frame 87
6185 RPN2 Ribophorin II
27063 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle)
29968 PSAT1 Phosphoserine aminotransferase 1
2152 F3 Coagulation factor III (thromboplastin, tissue factor)
81539 SLC38A1 Solute carrier family 38, member 1
6397 SEC14L1 SEC14-like 1 (S. cerevisiae)
10397 NDRG1 N-myc downstream regulated 1
5638 PRRG1 Proline rich Gla (G-carboxyglutamic acid) 1
10797 MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, met
2530 FUT8 Fucosyltransferase 8 (alpha (1,6) fucosyltransferase)
80115 BAIAP2L2 BAI1-associated protein 2-like 2
5209 PFKFB3 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3
10175 CNIH Cornichon homolog (Drosophila)involved in carcinogenesis and maintenance of a malignant phenotype
across several tumor entities (Table 4). These findings thus further
support our hypothesis that Hippo signaling might be a crucial driver
of carcinogenesis and represents a promising potential therapeutic
target in ccRCC.
Among the most prominently downregulated genes were two
members of the endothelin family, EDN1 and EDN2, as well as
c-Myc. Cross-validation of mRNA expression of these genes in
MZ1774, A498, and ACHN YAP knockdown cells confirmed
significant c-Myc and EDN1 down-regulation in MZ1774 and A498
on YAP knockdown (MZ1774: fold changes = 0.34 ± 0.006,
P b .0001 for c-Myc and 0.41 ± 0.009, P b .0001 for EDN1; A498:
fold changes = 0.79 ± 0.026, P = .0085 for c-Myc and 0.41 ± 0.019,
P = .0001 for EDN1, respectively; see Figure 5B). EDN2 expression
was significantly reduced in all three cell lines examined (fold
changes = 0.06 ± 0.003, P b .0001 for MZ1774, 0.62 ± 0.025,
P = .001 for A498, and 0.17 ± 0.0067, P b .0001 for ACHN,
respectively).
Of note, immunohistochemistry and real-time RT-qPCR con-
firmed consistent knockdown of YAP1 as well as down-regulation ofAccession No. Fold Change P Value
NM_001956.3 0.24 1.16E−11
NM_001955.4 0.31 8.57E−06
NM_003246.2 0.33 2.34E−05
NM_015675.3 0.34 7.53E−05
NM_001554.4 0.36 1.73E−04
NM_005776.2 0.37 3.02E−06
2;
III)
NM_001354.5 0.37 4.71E−06
NM_002467.4 0.37 1.05E−06
NM_001690.3 0.38 4.44E−12
NM_002467.4 0.38 2.34E−06
transport), member 2 NM_001012662.2 0.39 3.40E−06
NM_181655.2 0.39 7.44E−10
NM_001130145.2 0.40 2.42E−08
NM_030952.1 0.40 4.10E−05
NM_001160124.1 0.40 4.23E−04
NM_001178091.1 0.41 7.35E−08
NM_030952.1 0.41 5.60E−06
NM_006933.4 0.41 1.85E−07
NM_021629.3 0.42 2.34E−08
NM_018948.3 0.42 4.98E−09
NM_001199180.1 0.42 2.63E−07
NM_001142466.1 0.44 4.04E−08
NM_004864.2 0.44 8.31E−05
NR_029493.1 0.44 4.12E−07
NM_021804.2 0.44 2.76E−07
, member 5 NM_003486.5 0.44 9.39E−07
NM_001002296.1 0.44 1.41E−11
NM_001164507.1 0.44 2.93E−05
NM_001201329.1 0.44 4.58E−06
NM_005776.2 0.45 2.71E−05
NM_021158.3 0.46 8.68E−06
NM_001001436.2 0.46 1.76E−06
NM_002951.3 0.46 1.28E−07
NM_014391.2 0.47 2.80E−06
NM_021154.3 0.47 1.45E−04
NM_001993.4 0.47 4.45E−06
NM_001077484.1 0.48 1.17E−04
NM_001039573.2 0.48 3.67E−08
NM_001135242.1 0.48 5.34E−06
NM_000950.2 0.48 5.42E−08
henyltetrahydrofolate cyclohydrolase NM_006636.3 0.49 7.56E−08
NM_178155.2 0.49 3.76E−07
NM_025045.4 0.49 1.06E−05
NM_004566.3 0.49 3.49E−05
NM_005776.2 0.50 2.86E−05
Figure 5. Differential expression of selected genes was confirmed by real-time RT-qPCR. The graphs show normalized average steady-
state mRNA expression levels in YAPshRNA-transfected versus mock-transfected MZ1774 cells as means and SEM (A). Cross-validation
in other YAPshRNA-transfected ccRCC cell lines revealed uniform EDN2, CYR61, and THBS1 down-regulation as well as EDN1 and cMYC
down-regulation in two tested cell lines (B). YAP and TEAD1 are simultaneously present on selected TEAD1-binding sites in the promoter
regions of CTGF, MYC, EDN1, and EDN2 (C, D).
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Table 4. Signaling Pathways Affected by Knockdown of YAP in MZ1774 Cells.
KEGG Pathway ID pNDE pPERT pG pGFDR pGFWER Status KEGG Link
p53 signaling pathway 4115 1.524E−06 0.1260 3.1620E−06 0.0003 0.0003 Activated http://www.genome.jp/dbget-bin/show_pathway?
hsa04115+3486+1647+4616+7057+8795+54205+1021+27244
MAPK signaling pathway 4010 1.829E−04 0.3150 6.2009E−04 0.0248 0.0670 Inhibited http://www.genome.jp/dbget-bin/show_pathway?
hsa04010+11221+2247+627+9261+1649+51776+1647+4616+3554+4609+2872
Cell cycle 4110 6.475E−02 0.0010 6.8925E−04 0.0248 0.0744 Activated http://www.genome.jp/dbget-bin/show_pathway?hsa04110+1647+4616+1021+4609
KEGG,Kyoto encyclopedia of genes and genomes; pNDE, probability value for overrepresentation of differentially expressed genes in a given pathway; pPERT, probability value for abnormal perturbation of that
pathway, as measured by propagating measured expression changes across the pathway topology; pG, global probability value combining pNDE and pPERT; pGFDR, pG (after false discovery rate-correction);
pGFWER, pG (after familywise error rate-correction).
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xenografts of human ccRCCs as well (Figure 6, C and D).
To investigate a direct relationship between YAP and its putative
target genes in ccRCC, we performed ChIP-qPCR on selected regions
containing TEAD-binding motifs within the promoter region of
those genes (Figure 5C). A well-characterized YAP/TEAD1-binding
site in the promoter region of the bona fide YAP target gene CTGF
was selected as a positive control. We found YAP and TEAD to beFigure 6. YAP down-regulation inhibits tumor growth in a subcutane
cells into the flanks of CD1nu/nu mice resulted in significantly smaller
bodymass of themice (A, B). RT-PCR of freshly frozen xenograft tissue
derived from ACHN YAP knockdown cells (C). Hematoxylin and eosin
mock and ACHN YAP knockdown xenograft tissues illustrate down-re
in ×20, with insets in ×40 magnification.simultaneously present on the promoter regions of the MYC, EDN1,
as well as EDN2 genes in MZ1774 (Figure 5D).
YAP Expression Correlates with EDN2 Expression in
ccRCC Tumors
We next analyzed the expression of the thus identified proposed
downstream effector of YAP, EDN2, in primary tissue samples of
human ccRCC tumors using immunohistochemistry. YAP expressionous xenograft model. Subcutaneous injection of YAP knockdown
tumors compared to mock-transduced cells while not affecting the
confirmed significant down-regulation of YAP and EDN2 in tumors
stainings and immunohistochemistry of YAP and EDN2 in ACHN
gulation on the protein level (D). Representative images are shown
Table 5. Correlation of YAP and EDN2 Expression in ccRCC Tumors.
YAP Expression
Positive Weak or Negative Total
EDN2 Positive 20 3 23
Weak or negative 2 5 7
Total 22 8 30
Fisher exact test, P = .0067.
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.0067; Table 5). Figure 7 shows representative examples of two cases
exhibiting double positivity (A and B) or double negativity (C and D)
for YAP and EDN2, respectively.
Finally, Figure 8 summarizes our results and proposes a potential
mechanism of the proproliferative and proinvasive functions of YAP
in ccRCC by its interaction with the endothelin axis and the tumor
microenvironment.
Discussion
Our data presented here suggest widespread deregulation of the
Hippo signaling pathway in human ccRCC. In a considerable subset
of cases, this was found to be due to down-regulation of the upstream
regulator SAV1 and consecutive nuclear accumulation of YAP. In this
regard, our data are in line with a recent report by Matsuura and
colleagues, who describe down-regulation of SAV1 in high-grade
ccRCC [19]. Of note, copy number loss on chromosome 14q22, i.e.,
in the region of the SAV1 gene, have been previously described in
high-grade ccRCC by different groups [19-21]. In addition,
truncating mutations of this upstream member of the Hippo network
are present in a subset of VHL-wt ccRCCs [22,23]. However, our
data presented here also hint at the existence of other alternative
mechanisms of pathway perturbation in human ccRCC, since in a
considerable subset of cases in which marked, albeit not exclusively
nuclear staining for YAP was observed this was not accompanied by
loss of SAV1 expression.Figure 7. EDN2 expression correlates with YAP positivity in patients w
with ccRCC confirmed that EDN2 expression correlates with YAP pos
(A, B), whereas loss of YAP expression often results in minimal to abMoreover, our data suggest an important role of Hippo signaling in
mediating proliferation as well as migration and invasion, both in
vitro and in vivo, with obvious impact on the metastatic potential of
ccRCC. In line with our observations, conditional knockout of NF2,
an upstream activator of the growth inhibitory Hippo pathway, in the
proximal tubular epithelium of Villin-Cre;Nf2(lox/lox) mice leads to
intratubular neoplasia and invasive carcinoma that resembles human
RCC in a mouse model of RCC [24]. Recent reports also linked the
renal cilia-associated proteins NPHP4 and NPHP9 to Hippo
signaling in both oncogenically transformed and normal kidney
epithelial cells. These proteins were found to prevent Lats-dependent
phosphorylation of YAP, thus controlling YAP activation and
mediating cell proliferation [25,26]. Of note, Lamar et al. recently
described enhanced metastatic potential of breast cancer as well as
melanoma cells with increased YAP/TEAD activity; they concluded
that YAP can promote metastasis through its TEAD-interaction
domain [27]. To the best of our knowledge, our data presented here
for the first time hint at a possible link between Hippo signaling and
increased invasiveness and metastatic potential in ccRCC.
As a next step, we thought to further dissect the underlying
mechanism by which YAP exerts its proproliferative and potentially
proinvasive properties in ccRCC on a molecular level and to identify
downstream effectors of Hippo signaling in this entity, since this
might have important implications in exploiting this pathway as
potential therapeutic target in future work. Transcriptomic profiling
of MZ1774 YAP knockdown cells provided clues toward downstream
targets of YAP in ccRCC, including some genes that are known to be
overexpressed in ccRCC like members of the endothelin family, c-
Myc, and CDH6, and has been shown to promote tumor growth and
metastasis in experimental settings. We observed consistent down-
regulation of the bona fide YAP target gene CYR61 on YAP
knockdown in all cell lines examined. CYR61 is a positive regulator of
cell growth [28] and has been implicated as a proangiogenic factor in
highly vascularized RCC, acting alongside vascular endothelial
growth factor (VEGF) and exerting additive nonoverlappingith ccRCC. Immunohistochemistry of tumor tissues of 30 patients
itivity. Double positivity for YAP and EDN2 was frequently observed
sent EDN2 expression (C, D).
Figure 8. Putative interaction of YAP with the endothelin axis
in ccRCC.
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Hippel-Lindau protein expression, although its expression was only
partly dependent on Hypoxia-inducible factor 2-alpha function,
suggesting additional mechanisms that contribute to CYR61 up-
regulation in RCC [29]. Furthermore, recent reports linked CYR61
with integrin-mediated cell migration and invasion in prostate cancer
cell lines, hinting at a potential role in metastasis [30].
THBS1 is one of the most potent physiological antiangiogenic
factors and its expression has been reported as an independent
prognostic factor in ccRCC with retained expression being associated
with increased survival [31]. It is therefore somewhat surprising to
observe down-regulation of THBS1 mRNA on YAP knockdown in
all cell lines analyzed. YAP might interfere with the network of
proangiogenic and antiangiogenic factors, such as CYR61 and
THBS1, in ccRCC, tipping the balance toward a homeostasis that
favors the proliferation and survival of the tumor cells.
EDN1 and EDN2 were the most prominently downregulated
genes in MZ1774 cells on YAP knockdown. Endothelins are
important regulators of kidney function, and endogenous endothelin
is involved in the regulation of renal cell growth and proliferation, as
well as fluid and electrolyte excretion. Production of endothelins in
the kidney is increased in numerous renal diseases [32], and ccRCC
tumors have been reported to express EDN1 and its receptor ETA
with ccRCC cell lines secreting EDN1 [33,34]. The selective
endothelin-A receptor antagonist atrasentan has been used incombination with interferon-alpha in a phase I study in metastatic
RCC, albeit with moderate clinical antitumor effects [35].
The impact of YAP knockdown on EDN2 expression was most
pronounced and present in all three cell lines tested, whereas EDN1
down-regulation could be cross-validated in A498 but not in ACHN
YAP knockdown cells. As ACHN YAP knockdown cells displayed the
same phenotype in respect to reduced cancer cell proliferation and
migration and did form smaller xenograft tumors in vivo, EDN2
seems to be one of the main effectors responsible for these effects. In
line with this hypothesis, we found that YAP and EDN2 expression
correlates in clinical tumor specimen of patients with ccRCC as
assessed by immunohistochemistry. Research on the endothelin axis
in cancer has focused mainly on EDN1, and results have largely been
extrapolated to EDN2. It has been assumed that EDN2 would mimic
the actions of its more abundant counterpart EDN1, but recent
findings in vitro and in knockout mice underscore that EDN2 does
not simply amplify or duplicate EDN1 action and imply a distinct
function of EDN2 in physiological and pathophysiological processes
[36]. Furthermore, EDN2, and not the more abundant EDN1, was
first isolated from RCC cell lines [37]. A recent paper reported EDN2
expression to be a common and early event in patients with localized
ccRCC undergoing nephrectomy and proposed a potential role in
ccRCC progression [38]. An association of higher tumor expression
of EDN2 with longer progression-free survival could not be
confirmed after adjustment for known clinicopathologic factors and
it would be interesting to compare expression levels with tumors of
patients with advanced metastatic disease.
Grimshaw et al. reported an important influence of EDN2 on the
invasive potential of breast cancer cells and proposed a mechanism
where EDN2-secreting tumor cells provide chemotactic cues to
tumor-infiltrating macrophages, which in turn secrete matrix
metallopeptidase (MMP)-2 and MMP-9 to facilitate tumor cell
invasion and metastasis [39]. The observed effect was dependent on
both endothelin receptor B and MAPK signaling, and expression of
EDN2 and its receptor was stronger at the invasive margin of the
tumor tissue. Of note, we observed inhibition of the MAPK signaling
pathway on YAP knockdown in MZ1774 cells. Overexpression of
EDN2 increases the invasive potential of breast cancer cell lines
in vitro but is not sufficient to induce an invasive phenotype in benign
cells, indicating the cooperation with other signaling networks [40].
Concurrently, Said et al. reported an instrumental role of EDN1
signaling through endothelin receptor A in the development of
metastatic bladder cancer and delineated a proinvasive network
governed by members of the endothelin family involving direct
actions like the activation of proinflammatory transcription factors
such as activator protein 1 and nuclear factor kappa-light-chain-
enhancer of activated B cells in human monocytes and cancer cells
and the stimulation of the production of a range of proinvasive
cytokines like interleukin-6, cyclooxygenase 2, chemokine (C-C
motif) ligand 2 (CCL2), MMP-2, and MMP-9 as well as indirect
modulation of the tumor microenvironment by influencing tumor-
stroma interactions as well as tumor-associated immune cells [41].
These endothelin functions were instrumental in the process of
metastatic colonization, the first step of the establishment of a filial
tumor at a distant site, and pharmacologic blockade of endothelin
receptor signaling inhibited metastasis significantly in an experimen-
tal animal model, despite having only modest effects on primary
tumor growth. We observed that these reported target genes of EDN1
signaling, namely interleukin-6, COX2, VEGFA, and CCL2, were
320 YAP in ccRCC Schütte et al. Translational Oncology Vol. 7, No. 2, 2014also moderately but significantly downregulated in MZ1774 YAP
knockdown cells as determined by microarray or RT-PCR analysis
(fold changes were 0.74, P b .0008 for interleukin-6, 0.60, P = .002
for COX2, 0.67, P = .0065 for VEGFA, and 0.82, P = .032 for
CCL2, respectively).
Up-regulation of c-Myc expression has been reported to occur in a
majority of ccRCC cases [42,43], although amplification of theMYC
gene is only found in a small subset of cases [42,44] leading to the
assumption that c-Myc is activated by other mechanisms in addition
to amplification. We observed strong c-Myc down-regulation on YAP
knockdown in MZ1774 cells. c-Myc knockdown by siRNA in
ccRCC cell lines leads to a phenotype that resembles that of YAP
knockdown with marked inhibition of proliferation and anchorage-
independent growth [42]. c-Myc expression is stimulated by EDN1
through MAPK signaling in neoplastic cells [45,46], and our data
show inhibition of the MAPK signaling pathway along with EDN1
and concomitant c-Myc down-regulation on YAP knockdown in
MZ1774 and A498 cells, whereas mRNA expression levels of these
genes were not affected in ACHN cells, indicating that c-Myc might
additionally be an indirect target of YAP, downstream of EDN1 in
ccRCC. However, the MYC-promoter region features GT-IIC
consensus sequences as potential binding sites for the YAP/TEAD
complex, and indeed, these regions are enriched in ChIPs of MZ1774
lysates, underscoring the primary direct relationship. Previous studies
have also found pronounced c-Myc up-regulation on overexpression
of YAP in the murine liver [3].
CDH6 mRNA expression was found to be upregulated in
MZ1774 YAP knockdown cells. Normal renal epithelium and
RCC express multiple members of the cadherin family in a distinct
pattern with E-cadherin being expressed in Bowman's capsule and all
tubular segments except the proximal convoluted and straight tubules
[47]. Consequently, E-cadherin expression frequency in RCC is lower
than in other cancers and even low-grade tumors infrequently express
E-cadherin [48]. Conversely, CDH6 is expressed in proximal renal
tubules and RCC, especially when E-cadherin is absent, and seems
partly to take over E-cadherin function [49]. Detectable CDH6
mRNA from circulating tumor cells in the peripheral blood of
patients with RCC has been proposed as a prognostic marker
associated with increased risk of metastasis [49,50] hinting not
necessarily at an active role of the CDH6 protein in metastasis but
rather highlighting the inadequate ability of CDH6 to replace E-
cadherin in cell adhesion. Up-regulation of the cell adhesion molecule
CDH6 in response to YAP knockdown is therefore not contradictory
to a less invasive phenotype.
In light of the most recent report published by the Cancer
Genome Research Atlas Network [51], which found frequently
altered promoter methylation of miR-21 with subsequent high
miR-21 expression in high stage ccRCCs that inversely correlated
with outcome, it is intriguing to note the significant down-
regulation of miR-21 upon YAP knockdown. Recent work from
Dey et al. showed that miR-21 targets PTEN protein expression
and promotes ccRCC survival and invasion through Akt/TORC1
signaling [52].
Taken together, our data provide strong evidence that Hippo
signaling plays an important role in regulating proliferation,
invasiveness, and metastatic potential of ccRCC and might serve as
a target for therapeutic intervention in the future. Disrupted Hippo
signaling and consecutive derepression and activation of YAP lead to
increased production of the putative YAP target genes EDN1, EDN2,and c-Myc. Increased endothelin signaling in turn results in increased
production of proproliferative and proinvasive mediators by ccRCC
cells and might thus enhance metastatic colonization. Therefore,
future studies aimed at developing specific inhibitory drugs of the
Hippo signaling pathway or its downstream effectors described here
seem warranted to generate novel therapeutic regimens against
ccRCC.
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